AstraZeneca PLC Director/PDMR Shareholding (8636I)
March 30 2015 - 10:00AM
UK Regulatory
TIDMAZN
RNS Number : 8636I
AstraZeneca PLC
30 March 2015
Transaction by Persons Discharging Managerial
Responsibilities
Disclosure Rule DTR 3.1.4
On 27 March 2015, the individuals listed below, who are all
persons discharging managerial responsibilities, were granted
awards over the Company's ordinary shares or American Depositary
Shares (ADSs) under the terms of the AstraZeneca Deferred Bonus
Plan (AZDBP), the AstraZeneca Performance Share Plan (AZPSP) and
the AstraZeneca Investment Plan (AZIP). One ADS equals one ordinary
share.
Shares awarded Shares awarded Shares awarded Award price
Name under AZDBP under AZPSP under AZIP per share
Pascal Soriot 13,482 104,764 17,460 4762p
--------------- --------------- --------------- ------------
Marc Dunoyer 7,111 45,880 7,646 4762p
--------------- --------------- --------------- ------------
Briggs Morrison 2,620 22,457 3,742 $70.58
--------------- --------------- --------------- ------------
Luke Miels 1,570 24,412 4,068 4762p
--------------- --------------- --------------- ------------
The AZDBP award represents the portion of each individual's
annual bonus for 2014 that they are required to defer into shares.
The shares are subject to a three-year holding period (27 March
2015 to 26 March 2018).
The AZPSP award is subject to a combination of performance
measures focused on our scientific, commercial and financial
performance assessed over a three-year performance period (1
January 2015 to 31 December 2017). The award will vest on the third
anniversary of the date on which it was granted, except for awards
to Executive Directors, which will be subject to a further two-year
holding period before the award vests.
The AZIP award is subject to two performance hurdles relating to
dividend and dividend cover; both must be achieved in each year of
the four-year performance period (1 January 2015 to 31 December
2018) for the award to vest. The award is subject to a four-year
holding period, commencing at the end of the performance
period.
Details of the performance measures that relate to the AZPSP and
AZIP awards are available on the Company's website at
www.astrazeneca.com/Investors/Annual-reports.
On 30 March 2015, the interest of Dr Briggs Morrison, a person
discharging managerial responsibilities, in the American Depositary
Shares (ADSs) of AstraZeneca PLC changed as detailed below. One ADS
equals one ordinary share.
The change in interest relates to the vesting of awards of
shares made in March 2012 under the AstraZeneca Performance Share
Plan and the AstraZeneca Restricted Share Plan as set out in the
table below.
In respect of the award of shares under the AstraZeneca
Performance Share Plan, following the application of performance
measures specified at the time of grant, Dr Morrison has become
beneficially entitled to 50% of the shares originally awarded. In
accordance with the plan rules, any unvested part of the award has
immediately and irrevocably lapsed.
In respect of the award of shares under the AstraZeneca
Restricted Share Plan, in accordance with the terms of the award,
Dr Morrison has become beneficially entitled to all of the shares
originally awarded.
Sufficient vested shares have been withheld to cover certain tax
obligations arising on the vesting and the net number of shares has
been delivered into a personal brokerage account.
Shares Shares Shares Net shares
Plan awarded vested withheld received
AstraZeneca Performance
Share Plan 43,340 21,670 10,452 11,218
--------- --------- ---------- -----------
AstraZeneca Restricted
Share Plan 24,724 24,724 11,924 12,800
--------- --------- ---------- -----------
For tax purposes, the fair market value of the shares at vest
was $70.07 per share being the closing price of AstraZeneca ADSs on
the last trading day preceding the vesting day.
A C N Kemp
Company Secretary
30 March 2015
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSURUARVKAOOAR
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024